Method for treating or preventing Alzheimer's disease

• US 7,300,927 B2
• Filed: 09/23/2003
• Issued: 11/27/2007
• Est. Priority Date: 03/12/1997
• Status: Expired due to Fees

• Current Assignee: Jack R. Wands, Robert W. Esmond, Suzanne De La Monte
• Original Assignee: Jack R. Wands, Robert W. Esmond, Suzanne De La Monte
• Inventors: Wands, Jack R., de la Monte, Suzanne, Esmond, Robert W.
• Primary Examiner(s): Hartley; Michael G.
• Assistant Examiner(s): SAMALA, JAGADISHWAR RAO
• Application Number:
  US10/669,217
• Publication Number:
  US 20040060077A1
• Time in Patent Office: 1,526 Days
• Field of Search: 514/655, 514/369, 514/188, 424/23
• US Class Current: 514/369
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/48 Ergoline derivatives, e.g. lysergic acid, ergotamine
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system

Abstract

Disclosed is a method for treating or preventing Alzheimer'"'"'s disease by restricting the level of metabolizable carbohydrate in the diet and/or administering to the patient an effective amount of an agent which reduces serum insulin levels.

Claims

1. A method for the treatment of Alzheimer'"'"'s disease, in a human, comprising administering to the human in need thereof an effective amount of an agent, wherein the agent is selected from chromium, human insulin-like growth factor-I and a thiazolidinedione, wherein the agent increases the insulin sensitivity of the human, and restricting the metabolizable carbohydrates in the diet of the human to no more than about 55 grams per day.

2. The method of claim 1, wherein the metabolizable carbohydrates in the diet are limited to no more than about 30 grams per day.

3. The method of claim 1, wherein the metabolizable carbohydrates in the diet are limited to no more than about 15 grams per day.

4. The method of claim 1, wherein the metabolizable carbohydrates in the diet are limited to no more than about 10 grams per day.

5. The method of claim 1, wherein said agent is a thiazolidinedione.